Evidence map›Paper›PMID 41504889›Full record

Trial reportIntensive care medicine2026

Cyclosporine versus placebo pretreatment of brain-dead donors and kidney graft function (Cis-A-Rein trial): a multicenter, double-blind, randomized, controlled trial.

Carole Ichai, Eric Fontaine, Karine Baumstarck, Thomas Rimmelé, Guillaume Strecker, Mohamed Boucekine, Vivien Szabo, Clément Gosset, Anne-Elisabeth Heng, Thomas Kerforne and 13 more

Erratum issued Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Intensive care medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02907554 (Effects of Cyclosporine A Pretreatment of Deceased Donor on Kidney Graft Function), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02907554 phase4completednot on this map

Effects of Cyclosporine A Pretreatment of Deceased Donor on Kidney Graft Function: A Randomized Controlled Trial

TypeinterventionalSponsorUniversity Hospital, Clermont-FerrandRan2017 to 2023Enrolled648ConditionsBrain Death, Kidney TransplantationArmscyclosporine A, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Carole IchaiUniversity of Côte d'Azur, Anesthesia and Critical Care Department, Pasteur 2, University of Nice, Nice, France. carole.ichai@univ-cotedazur.fr.ORCID 0000-0002-0251-1280
Eric FontaineResearch Unit INSERM U1055 LBFA, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France.
Karine BaumstarckClinical Research Unit, Epidemiology and Health Economics Department, University Hospital of Marseille, University of Marseille Méditerranée, Marseille, France.
Thomas RimmeléAnesthesia and Critical Care Department, Edouard Herriot, University of Lyon, Lyon, France.
Guillaume StreckerEmergency and Trauma Care Unit, Organ and Tissue Procurement and Transplantation Network, University of Lille, Lille, France.
Mohamed BoucekineClinical Research Unit, Epidemiology and Health Economics Department, University Hospital of Marseille, University of Marseille Méditerranée, Marseille, France.
Vivien SzaboFonctional Genomic Institute, Research Unit CNRS UMR5203, INSERM U1191, Anesthesia and Critical Care Department, Gui de Chauliac, University of Montpellier, Montpellier, France.
Clément GossetNephrology and Renal Transplantation Unit, Pasteur 2, University of Nice, Nice, France.
Anne-Elisabeth HengResearch Unit UMR 1019, INRA, UNH, CRNH, Nephrology Department, University of Clermont-Ferrand, Clermont-Ferrand, France.
Thomas KerforneResearch Unit INSERM U 1313, IRMETIST, Cardiovascular Anesthesia and Critical Care Department, University of Poitiers, Poitiers, France.
Edouard NaboulsiAnesthesia and Critical Care Department, University of Toulouse, Toulouse, France.
Lionel VellyResearch Unit MeCA, Neurosciences Institute of Timone-UMR 7289, La Timone, University of Marseille Méditerranée, Marseille, France.
Marc LeoneAnesthesia and Critical Care Department, Nord Hospital, University of Marseille Méditerranée, Marseille, France.
Julien PottecherResearch Unit FHU DATA-SURG ER 3072, FMTS, Anesthesia, Perioperative and Critical Care Department, University of Strasbourg, HautepierreStrasbourg, France.
François DépretAnesthesia and Surgical Critical Care Department, Burns Critical Care, Saint-Louis-Lariboisière-Fernand Vidal, University of Paris Cité, Paris, France.
Dimitri MargetisAnesthesia and Critical Care Department, Pitié-Salpêtrière, University of Paris Sorbonne, Paris, France.
Bélaïd BouhemadAnesthesia and Surgical Critical Care Department, University of Dijon, Dijon, France.
Jean-Christophe OrbanUniversity of Côte d'Azur, Anesthesia and Critical Care Department, Pasteur 2, University of Nice, Nice, France.
Audrey LeroyOrgan and Tissue Procurement and Transplantation Network, Pasteur 2,, University of Nice, Nice, France.
Bruno RiouResearch Unit UMRS 1166, IHU ICAN, Organ and Tissue Procurement and Transplantation Network, Pitié Salpêtrière, University of Paris Sorbonne, Paris, France.
Lucile BoraoClinical Research Department, University of Clermont-Ferrand, Clermont-Ferrand, France.
Jean-Michel ConstantinResearch Unit GRC 29, AP-HP, DMU DREAM, Anesthesia and Critical Care Department, Pitié-Salpêtrière, University of Paris Sorbonne, Paris, France.
Cis-A-Rein Group

Funding

French Ministry of health 2016 AOM 15-296French Ministry of health PHRC-N
6 · The paper itself

Abstract

purposeDelayed graft function is the most frequent early complication of kidney transplantation. Pretreatment of kidney donors with cyclosporine has decreased delayed graft function in animal studies by reducing ischemia-reperfusion graft injuries. No randomized clinical trials have assessed the efficacy of cyclosporine pretreatment of brain-dead donors in reducing delayed graft function.

methodsIn this multicenter randomized, double-blind, and placebo-controlled trial, brain-dead donors were randomized (1:1) to receive either 2.5 mg/kg of cyclosporine or a glucose placebo infusion. The kidney transplant candidates were allocated through their donor assignment. The primary outcome was the occurrence of delayed graft function (DGF), defined as the need for at least one hemodialysis within the 7 days after kidney transplantation. Secondary outcomes included early graft function parameters within the 7 days post-transplantation, and 1-year graft and recipient survival.

resultsBetween December 17, 2017 and March 3, 2023, 258 donors/331 recipients in the placebo group and 238 donors/312 recipients in the cyclosporine group were included in the modified intention-to-treat analysis. DGF occurred in 46 recipients (13.9%) in the placebo group and in 53 recipients (17.0%) in the cyclosporine group (unadjusted odd ratio = 1·27, 95% CI 0.83-1.95, P = 0.28). No significant between-group differences in the secondary outcomes (early graft function and 1-year graft and recipient survival) were observed.

conclusionIn this double-blind, randomized controlled clinical trial, a pretreatment of brain-dead donors with a single low dose of cyclosporine did not significantly reduce the occurrence of DGF in kidney transplant recipients.

Indexed as

Brain DeathCyclosporineDelayed Graft FunctionKidney TransplantationTissue DonorsAdultDouble-Blind MethodFemaleGraft SurvivalHumansImmunosuppressive AgentsMaleMiddle AgedCyclosporineImmunosuppressive AgentsBrain dead donorsCyclosporineDelayed graft functionKidney transplantation

Identifiers

PMID41504889

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.